Infectious diseases caused by viruses become a serious public health issue in the recent past, including current pandemic situation of COVID-19. Enveloped viruses are most commonly known to cause emerging and recurring infectious diseases. Viral and cell membrane fusion is the major key event in case of enveloped viruses that required for their entry into the cell. Viral fusion proteins are playing important role in fusion process and in infection establishment. Because of this, fusion process targeting antivirals become an interest to fight against viral diseases caused by enveloped virus. Lower respiratory tract infections casing viruses like influenza, respiratory syncytial virus (RSV) and severe acute respiratory syndrome corona virus (SARS-CoV) are examples of such enveloped viruses that are at top in public health issues. Here, we summarized the viral fusion protein targeted antiviral peptides along with their mechanism and specific design to combat viral fusion process. The pandemic COVID-19, severe respiratory syndrome disease is outbreak worldwide. There are no definitive drugs yet but few are in on-going trial. Here, an approach of fragment based drug design (FBDD) methodology was used to identify the broad spectrum agent target to the conserved region of fusion protein of SARS CoV-2. Three dipeptides (DL, LQ and ID) were chosen from the library and designed by the systematic combination along with their possible modifications of amino acids to the target sites. Designed peptides were docked with targeted fusion protein after energy minimization. Results show strong and significant binding affinity (DL = -60.1 kcal/mol; LQ = -62.8 kcal/mol; ID= -71.5 kcal/mol) during interaction. Any one of the active peptides from the developed libraries may help to block competitively the target sites to successfully control COVID-19.

中文翻译：

---

融合蛋白靶向抗病毒肽：基于片段的药物设计（FBDD）指导针对SARS-CoV-2的二肽的合理设计。

近年来，由病毒引起的传染病已成为严重的公共卫生问题，其中包括当前的COVID-19大流行情况。包膜病毒最常引起新出现和复发的传染病。病毒和细胞膜融合是包膜病毒进入细胞所需的主要关键事件。病毒融合蛋白在融合过程和感染建立中起着重要作用。因此，针对抗病毒剂的融合过程成为对抗由包膜病毒引起的病毒性疾病的兴趣。下呼吸道感染肠衣病毒，如流感病毒，呼吸道合胞病毒（RSV）和严重急性呼吸系统综合症冠状病毒（SARS-CoV），是这类被包膜病毒的例子，在公共卫生领域处于最高地位。这里，我们总结了靶向病毒融合蛋白的抗病毒肽，以及它们对抗病毒融合过程的机制和具体设计。大流行的COVID-19，严重的呼吸综合征疾病在世界范围内正在爆发。目前尚无最终药物，但正在进行的试验很少。在这里，使用基于片段的药物设计（FBDD）方法的方法来识别针对SARS CoV-2融合蛋白保守区域的广谱药物靶标。从文库中选择了三个二肽（DL，LQ和ID），并通过系统的组合以及它们对靶位点氨基酸的可能修饰来设计。能量最小化后，设计的肽与靶向融合蛋白对接。结果显示出强大而显着的结合亲和力（DL = -60.1 kcal / mol； LQ = -62.8 kcal / mol； ID = -71。5 kcal / mol）。来自开发的文库的任何一种活性肽都可以帮助竞争性地阻断靶位点，从而成功地控制COVID-19。